Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
Case Study: Keytruda The $100 Billion Exclusivity Question Mercks pembrolizumab product Keytruda is the worlds best-selling drug at $20.9 billion in 2023 global revenues [25]
RGD-modified polymer and liposome nanovehicles: Recent research progress for drug delivery in cancer therapeutics
Abigail Spanberger, and Adrian Smith, introduced bipartisan legislation in both houses of Congress that would modify the FDA definition of a shortage
A sensitivity analysis excluding the ITCA trial yielded consistent results (HR (95%CI): 0.86 (0.810.93)
US$ 26.05
US$ 20.84
US$ 29.38
US$ 22.55
US$ 20.10
